ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc (APLS)

26.90
-0.50
(-1.82%)
Closed 10 October 7:00AM
26.90
0.00
( 0.00% )
Pre Market: 7:00PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
26.90
Bid
25.08
Offer
27.00
Volume
-
0.00 Day's Range 0.00
26.545 52 Week Range 73.80
Market Cap
Previous Close
26.90
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
2,017,803
Shares Outstanding
121,766,328
Dividend Yield
-
PE Ratio
-6.23
Earnings Per Share (EPS)
-4.32
Revenue
396.59M
Net Profit
-525.63M

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the... Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
-
Apellis Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker APLS. The last closing price for Apellis Pharmaceuticals was US$26.90. Over the last year, Apellis Pharmaceuticals shares have traded in a share price range of US$ 26.545 to US$ 73.80.

Apellis Pharmaceuticals currently has 121,766,328 shares in issue. The market capitalisation of Apellis Pharmaceuticals is US$3.28 billion. Apellis Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.23.

Apellis Pharmaceuticals (APLS) Options Flow Summary

Overall Flow

Bullish

Net Premium

2M

Calls / Puts

300.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

APLS Latest News

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals,Β Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a...

Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day

WALTHAM, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals,Β Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the UBS Virtual Ophthalmology Day on...

Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination

WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals,Β Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.63-5.7132842621828.5329.526.545426572127.60614201CS
4-11.17-29.340688205938.0738.6926.545309741330.13499746CS
12-12.88-32.378079436939.7841.9426.545201780333.74658206CS
26-26.81-49.916216719453.7157.8526.545171420937.90128167CS
52-15.79-36.987584914542.6973.826.545178688848.01203648CS
156-6.45-19.340329835133.3594.7519.8301180575749.6238217CS
2602.7611.433305716724.1494.7516.85147328146.95929221CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BLMZBloomZ Inc
US$ 1.17
(63.59%)
1.67M
TVGNTevogen Bio Holdings Inc
US$ 0.40
(54.26%)
7.48M
ALLKAllakos Inc
US$ 0.86
(32.29%)
9
CNEYCN Energy Group Inc
US$ 0.685
(30.03%)
2.41M
WHLRWheeler Real Estate Investment Trust Inc
US$ 12.35
(26.54%)
200.98k
TOIIWOncology Institute Inc
US$ 0.0155
(-38.98%)
218
GRTSGritstone bio Inc
US$ 0.1402
(-29.33%)
210.8k
KLTOKlotho Neurosciences Inc
US$ 0.3801
(-26.89%)
6.26k
MRSNMersana Therapeutics Inc
US$ 1.48
(-21.28%)
500
TXG10x Genomics Inc
US$ 16.49
(-20.76%)
71.31k
JTAIJet AI Inc
US$ 0.1101
(18.90%)
11.19M
TVGNTevogen Bio Holdings Inc
US$ 0.40
(54.26%)
7.48M
KXINKaixin Holdings
US$ 0.2685
(8.70%)
3.41M
DUOFangDD Network Group Ltd
US$ 2.08
(18.18%)
2.62M
CNEYCN Energy Group Inc
US$ 0.685
(30.03%)
2.41M

APLS Discussion

View Posts
Monksdream Monksdream 4 weeks ago
APLS at a bottom channel
πŸ‘οΈ0
Dennisb68 Dennisb68 10 months ago
$60.00, that didn’t take long!
πŸ‘οΈ0
Dennisb68 Dennisb68 10 months ago
I like the way this traded today, $60 in the near future on news?
πŸ‘οΈ0
Dennisb68 Dennisb68 1 year ago
Holding up well..
πŸ‘οΈ0
doholic11 doholic11 1 year ago
Finally! Back up 14% today.
πŸ‘οΈ0
pitacorp pitacorp 1 year ago
Shorts got another 12 to 13% since you're warning, let's hope your warning sticks today...
πŸ‘οΈ0
Stockexpertpro Stockexpertpro 1 year ago
APLS Time to Cover Shorts just like i told the shorts last week on ARGX to Buy to Cover
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Closed out of puts at 99% profit on this one. Only three week hold.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Why is stock up so much???
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Stock up big today.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
FDA announcement soon.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Puts are very pricey and out of the money. Sell for cash to acct.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Why up today? As stock goes up, puts go up too. Strange.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Will we get FDA approval???
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
Heavy premium in the puts and calls.
πŸ‘οΈ0
IPO$ IPO$ 2 years ago
2/8/23 regulatory decision due on Empavali.
πŸ‘οΈ0
conix conix 2 years ago
Huge Market

πŸ‘οΈ0
conix conix 2 years ago
Drug trial for dry AMD slows progression of disease

Posted: Tuesday 29 March 2022

A drug being trialled for dry age-related macular degeneration (AMD) can significantly reduce the progression of the disease, according to new studies.

Phase three trials have shown that injections of a drug called pegcetacoplan resulted in a significant reduction in the rate at which the cells of the macular degenerate.

The studies by Apellis Pharmaceuticals built on previous research which showed that dry AMD is linked to the complement system and a hyperactive immune response that damages the eyes. Pegcetacoplan is a complement system inhibitor, meaning it aims to prevent this response from happening and harming healthy cells and tissue.

The studies involved two phase three clinical trials (DERBY and OAKS) involving more than 1,250 patients with late stage dry AMD, often referred to as geographic atrophy (GA). As part of the trials some patients received injections monthly, while others received them every other month.

In the combined results of the two trials, patients who received the drug monthly showed up to a 21% reduction in progression of the disease after 18 months, while those who were injected every other month had a 17% reduction.

Jeffrey S. Heier, principal investigator of the DERBY study from Ophthalmic Consultants of Boston, said: β€œIt is exciting to see these positive data with pegcetacoplan, which showed continuous and potentially improving effects over time. These 18-month results provide further evidence that pegcetacoplan meaningfully slows disease progression and has the potential to preserve vision longer.”

He added: β€œIn my practice, I have seen how devastating it can be for people living with GA to lose more of their vision year after year. There is an urgent unmet need in GA, and these results reinforce the potential of pegcetacoplan to become the first-ever treatment for patients with this debilitating disease.”

The study also found that pegcetacoplan was generally safe and well tolerated by those on the trial.

Results of the studies are to be submitted to the US Food and Drug Administration (FDA) for review by the end of June 2022, with the hope that the drug will be licenced for use in the USA.
πŸ‘οΈ0
PickleNick PickleNick 3 years ago
Going back to 60 this week
πŸ‘οΈ0
wantprofits wantprofits 5 years ago
looks like insider dumping may be happening again.. damnit
πŸ‘οΈ0
Pedro2004 Pedro2004 5 years ago
Be careful with this company.
There was a great PR.
An insider dump.
Then a 7 million share under-market private placement.
Then another insider dump the next day.

Scam company.
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $APLS Video Chart 01-07-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ComptonBrosInc ComptonBrosInc 5 years ago
First! Holding $40 2/21 call... waiting on trial results!
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock